Cellular responses to DNA damage are important determinants of both cancer development
and cancer outcome following radiation therapy and chemotherapy. Identification of …

Abstract O-6-methylguanine-DNA methyltransferase (MGMT) is an abundantly expressed
nuclear protein dealkylating O6-methylguanine (O6-MG) DNA residue, thus correcting the …

Background Markers of systemic inflammation are correlated with patient survival in various
cancers. The prognostic value of neutrophil-to-lymphocyte ratio (NLR) was compared with …

Temozolomide (TMZ) increases the overall survival of patients with glioblastoma (GBM), but
its role in the clinical management of diffuse low-grade gliomas (LGG) is still being defined …

Background Expression of the telomerase reverse transcriptase (TERT) might be altered by
activating mutations of the rs2853669 polymorphism within the promoter region. Here we …

The diffuse gliomas are primary central nervous system tumors that arise most frequently in
the cerebral hemispheres of adults. They are currently classified as astrocytomas …

Gliomas are a large and diverse group of primary brain tumors that include those that are
diffusely infiltrative and others that are well-circumscribed and low grade. Diffuse gliomas …

Purpose To evaluate 2 specific radiation schedules, each combined with temozolomide
(TMZ), assessing their efficacy and safety in patients aged≥ 65 years with newly diagnosed …

DNA sequencing is now faster and cheaper than ever before, due to the development of
next generation sequencing (NGS) technologies. NGS is now widely used in the research …

Prognosis for patients with glioblastoma continues to be limited, despite an aggressive,
multimodal treatment including alkylating chemotherapy. Temozolomide, the most widely …